ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

ACRX AcelRX Pharmaceuticals Inc

0.86
0.00 (0.00%)
Pre Market
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
AcelRX Pharmaceuticals Inc NASDAQ:ACRX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.86 0.861 0.89 0 01:00:00

AcelRx to announce first quarter 2018 results and provide a corporate update on Wednesday, May 9th, 2018

25/04/2018 9:30pm

PR Newswire (US)


AcelRX Pharmaceuticals (NASDAQ:ACRX)
Historical Stock Chart


From Oct 2019 to Oct 2024

Click Here for more AcelRX Pharmaceuticals Charts.

REDWOOD CITY, Calif., April 25, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release first quarter financial results after market close on Wednesday, May 9th, 2018. AcelRx management will host an investment-community conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on May 9th, 2018 to discuss the financial results and provide a corporate update.

Investors who wish to participate in the conference call may do so by dialing (866) 361-2335 for domestic callers, (855) 669-9657 for Canadian callers or (412) 902-4204 for international callers. Those interested in listening to the conference call live via the Internet may do so by visiting the Investors page of the company's website at www.acelrx.com and clicking on the webcast link on the Investors home page.

A webcast replay will be available on the AcelRx website for 90 days following the call by visiting the Investor page of the company's website at www.acelrx.com.

About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised setting. AcelRx's proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. The company has two product candidates including DSUVIA™ (sufentanil sublingual tablet, 30 mcg), known as DZUVEO outside the United States, with a proposed indication for the treatment of moderate-to-severe acute pain in medically supervised settings, and ZALVISO® (sufentanil sublingual tablet system, SST system, 15 microgram) being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in medically supervised settings.

For additional information about AcelRx's clinical programs, please visit www.acelrx.com.

AcelRx logo. (PRNewsFoto/AcelRx Pharmaceuticals, Inc.) (PRNewsfoto/AcelRx Pharmaceuticals, Inc.)

 

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/acelrx-to-announce-first-quarter-2018-results-and-provide-a-corporate-update-on-wednesday-may-9th-2018-300636575.html

SOURCE AcelRx Pharmaceuticals, Inc.

Copyright 2018 PR Newswire

1 Year AcelRX Pharmaceuticals Chart

1 Year AcelRX Pharmaceuticals Chart

1 Month AcelRX Pharmaceuticals Chart

1 Month AcelRX Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock